Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
UP FRONT MATTERSEditorials
You have accessRestricted Access

Effect of Membrane Permeability on Survival of Hemodialysis Patients

Alfred K. Cheung and Tom Greene
JASN March 2009, 20 (3) 462-464; DOI: https://doi.org/10.1681/ASN.2009010030
Alfred K. Cheung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Greene
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

The biologic plausibility of clinical benefits of high-flux compared with low-flux hemodialysis is supported by observations that numerous molecules with known biologic activities and potentially harmful effects accumulate in the plasma of patients with ESRD and are preferentially cleared by high-flux dialysis. In addition to β2-microglobulin, which is often used as a plasma marker, examples of these toxic middle molecules include parathyroid hormones, advanced glycation products of various molecular weights,1 leptin,2 apolipoprotein C-III,3 and several molecules that inhibit granulocyte functions.4 Empirical support for the clinical benefits of high-flux dialysis is provided by observational studies that report associations of high-flux dialysis with reduced mortality5; however, the Hemodialysis (HEMO) Study, a randomized trial performed in 1846 hemodialysis patients in the United States between 1995 and 2001, failed to demonstrate a decrease in its primary end point of all-cause mortality (hazard ratio [HR] 0.92; 95% confidence interval [CI] 0.81 to 1.05) with high-flux compared with low-flux dialysis.6 Nonetheless, because the lower limit of the CI could not rule out an overall hazard reduction of up to 19% and because secondary analyses showed trends favoring high flux for all-cause mortality in patients with >3.7 yr of previous dialysis7 and for cardiac mortality in the full cohort,6,8 the possibility of a moderate benefit of high-flux dialysis could not be excluded definitively.

The seminal report of the randomized comparison of high-flux versus low-flux groups in the Membrane Permeability Outcome (MPO) Study by Locatelli et al.9 in this issue of JASN provides valuable new information on this important question. Because the precision of estimated HRs depends on the number of outcome events, the precision of the MPO Study, with 162 deaths, was less than that of the HEMO Study, with 871 deaths6; however, the MPO Study provides key information on the effect of flux in a different setting. For example, MPO Study patients were more likely than the HEMO Study patients to be white and to use native fistulas10 and tended to have lower comorbidity than the HEMO Study patients (24 versus 45% with diabetes and 27 with cardiovascular disease versus 80% with cardiac disease at baseline, and 8.2 versus 16.6 deaths per 100 patient-years during the trial6). Perhaps more important, the MPO Study enrolled incident hemodialysis patients, whereas the mean dialysis duration at entry in the HEMO Study was 3.7 yr. By studying incident patients, the MPO Study avoided the complication that the treatment effects might be altered by previous exposure to low-flux or high-flux dialysis but incurred the risk that enhanced dialytic middle-molecule removal by the high-flux intervention might be overshadowed by residual kidney function in the months or years close to dialysis initiation.

There were also key differences between the trial interventions and conduct. In contrast to the HEMO Study, which was performed in a setting of predominant dialyzer reuse,11 dialyzers in the MPO Study were not reused. Requirements for inclusion of low-flux and high-flux dialyzers were based on membrane β2-microglobulin sieving coefficients in the MPO Study. In contrast, mean clinical β2-microglobulin clearances were used as part of the criteria in the HEMO Study.6,7,11 The use of different definitions for high flux complicates the comparison of membrane permeability, although it is possible that the high-flux arm in the MPO study had a higher mean β2-microglobulin clearance than the high-flux arm in the HEMO Study.

The primary analysis of the effect of high flux on mortality in the full MPO Study cohort indicates a trend favoring high flux that did not reach statistical significance; however, the MPO Study reports a statistically significant interaction of the flux intervention with baseline serum albumin level, with a nominally significant benefit reported in the subgroup characterized by serum albumin ≤4 g/dl (HR 0.63; 95% CI 0.45 to 0.90). Thus, the interpretation of the MPO Study is centrally related to the general problem of interpreting positive subgroup results in the setting of a negative finding in the full cohort. The evidence supporting a benefit in patients with hypoalbuminemia is strengthened because this subgroup was the original targeted population of the trial,9,12 and separate analyses for the two albumin subgroups were preplanned when the subgroup with normoalbuminemia was added. This a priori focus on the subgroup with hypoalbuminemia reduces the likelihood of a spurious finding as a result of multiple comparisons. This stands in contrast, for example, to the HEMO Study subgroup result in patients with >3.7 yr of previous dialysis, which was investigated as one of seven subgroup factors, although the subgroup analyses were also preplanned. Nonetheless, the plausibility of the positive MPO finding in the subgroup with hypoalbuminemia is somewhat reduced by the absence of a similar finding in the HEMO Study, which found no evidence of a greater benefit of high flux in patients with hypoalbuminemia.7

Joint analyses of the HEMO and MPO databases may be useful for further investigation of the combined evidence from these two studies. At this point, our best assessment of the range of the plausible benefits of high flux is provided by the 95% CIs for the mortality HRs in the full cohorts corresponding to the settings of the two studies, which were 0.81 to 1.05 and 0.56 to 1.04 in the HEMO Study and MPO Study, respectively. Given relatively strong arguments for the biologic plausibility of advantages of high flux, these intervals can be considered to be consistent with some clinical benefits of high flux, although they leave open the possibility of no benefit because both intervals overlap with 1.0. Of importance, neither the MPO Study nor the HEMO Study suggested harmful effects associated with high flux. It is yet to be determined whether more definitively positive results can be observed using membranes or techniques that permit even greater removal of middle molecules, such as hemodiafiltration, which achieves β2-microglobulin clearances of >100 ml/min.13 In the meantime, despite some remaining uncertainty, the results of the MPO Study can be interpreted as a supporting rationale for the use of high-flux dialysis membranes if they are financially affordable.

Disclosures

A.K.C. and T.G. were investigators in the HEMO Study. A.K.C. is also a consultant of Baxter Corporation.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Effect of Membrane Permeability on Survival of Hemodialysis Patients,” on pages 645–654.

  • Copyright © 2009 by the American Society of Nephrology

References

  1. ↵
    Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325 : 836– 842, 1991
    OpenUrlCrossRefPubMed
  2. ↵
    Coyne DW, Dagogo-Jack S, Klein S, Merabet E, Audrain J, Landt M: High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Am J Kidney Dis 32 : 1031– 1035, 1998
    OpenUrlCrossRefPubMed
  3. ↵
    Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P: Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 25 : 258– 262, 1999
    OpenUrlCrossRefPubMed
  4. ↵
    Haag-Weber M, Hörl WH: Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Nephrol Dial Transplant 11[ Suppl 2]: 98– 100, 1996
    OpenUrlPubMed
  5. ↵
    Krane V, Krieter DH, Olschewski M, März W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 49 : 267– 275, 2007
    OpenUrlCrossRefPubMed
  6. ↵
    Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 : 2010– 2019, 2002
    OpenUrlCrossRefPubMed
  7. ↵
    Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Nephrol 14 : 3251– 3263, 2003
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, HEMO Study Group: Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 65 : 2380– 2389, 2004
    OpenUrlCrossRefPubMed
  9. ↵
    Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R, Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 20 : 645– 654, 2009
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Allon M, Ornt DB, Schwab SJ, Rasmussen C, Delmez JA, Greene T, Kusek JW, Martin AA, Minda S, Hemodialysis (HEMO) Study Group: Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Kidney Int 58 : 2178– 2185, 2000
    OpenUrlCrossRefPubMed
  11. ↵
    Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK, Hemodialysis (HEMO) Study Group: Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. J Am Soc Nephrol 10 : 117– 127, 1999
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R: The effect of membrane permeability on ESRD: Design of a prospective randomised multicentre trial. J Nephrol 12 : 85– 88, 1999
    OpenUrlCrossRefPubMed
  13. ↵
    Krieter DH, Falkenhain S, Chalabi L, Collins G, Lemke HD, Canaud B: Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int 67 : 349– 356, 2005
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 20 (3)
Journal of the American Society of Nephrology
Vol. 20, Issue 3
March 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Effect of Membrane Permeability on Survival of Hemodialysis Patients
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Membrane Permeability on Survival of Hemodialysis Patients
Alfred K. Cheung, Tom Greene
JASN Mar 2009, 20 (3) 462-464; DOI: 10.1681/ASN.2009010030

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Effect of Membrane Permeability on Survival of Hemodialysis Patients
Alfred K. Cheung, Tom Greene
JASN Mar 2009, 20 (3) 462-464; DOI: 10.1681/ASN.2009010030
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

UP FRONT MATTERS

  • COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation
  • The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
  • Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
Show more UP FRONT MATTERS

Editorials

  • The Road Ahead for Research on Air Pollution and Kidney Disease
  • Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation
  • Animal Model of Pregnancy after Acute Kidney Injury Mirrors the Human Observations
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Effect of Membrane Permeability on Survival of Hemodialysis Patients
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire